Company CVAbout NGL Fine Chem Ltd 
NGL Fine Chem Ltd
Micro Cap
Pharmaceuticals & Biotechnology
NGL Fine-Chem Limited was incorporated on December 18, 1981 as a Private Limited Company in the State of Maharashtra. The Company became a Public Limited Company. The Company has got its registered office and factory at New Bombay. It was promoted by Mr. A.G.Lawande, Mr.R. J. Nachane joined Mr.A.G.Lawande for actively participating in the Management of the Company in 1989. The Company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health.
Company Coordinates
Company Details
301 E Square Subhash Road, Vile Parle (East) Mumbai Maharashtra : 400057
Registrar Details
Purva Shareregistry (India) Pvt Ltd , Gala No 9, Shiv Shakti, Industrial Estate,Sitaram Mill Comp., J R Boricha Marg, Lower Parel [E], Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR None Cr
Number of Shares
None Cr
Face Value
INR None
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
No Details Available.
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 2 Schemes (0.0%)
FIIs
Held by 1 FIIs (0.0%)
Promoter with highest holding
Rajesh Lawande (21.89%)
Highest Public shareholder
None
Individual Investors Holdings
23.0%
Board of Directors
Management
Designation
Remuneration
Rahul J Nachane
Managing Director
1.6 cr
Rajesh N Lawande
Whole Time Director & CFO
1.58 cr
Milind V Shinde
Chairman & Independent Directo
5.25 lacs
Ajita Nachane
Non-Exec & Non-Independent Dir
4.7 lacs
Jayaram Sitaram
Non-Exec. & Independent Dir.
4.4 lacs
Pallavi Pednekar
Company Sec. & Compli. Officer
0
Sarala Menon
Independent Director
3.5 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Raw material consumed
71.46293
0%
Raw material consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Sale of Products - Pharmaceutical Goods
150.78
98.43%
Other Operating Revenues - Duly Drawback and Other Export Incentives
2.40
1.57%
Sale of Products - Pharmaceutical Goods
Sale of Products - Pharmaceutical Goods
Other Operating Revenues - Duly Drawback and Other Export Incentives
Other Operating Revenues - Duly Drawback and Other Export Incentives
Stock DNARevenue and Profits:
Net Sales:
120 Cr
(Quarterly Results - Sep 2025)
Net Profit:
10 Cr
Pharmaceuticals & Biotechnology
INR 779 Cr (Micro Cap)
39.00
34
0.13%
0.11
6.89%
2.68
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
